Brinker Capital Inc. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,972 shares of the company’s stock after selling 8,701 shares during the period. Brinker Capital Inc.’s holdings in Novo Nordisk A/S were worth $9,443,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Bruderman Asset Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Karp Capital Management Corp acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $43,000. We Are One Seven LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $46,000. Highwater Wealth Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $49,000. Finally, Berman Capital Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 7.08% of the company’s stock.
NVO stock opened at $50.89 on Friday. Novo Nordisk A/S has a 1 year low of $41.23 and a 1 year high of $51.64. The company has a market capitalization of $124.35 billion, a P/E ratio of 20.19, a P/E/G ratio of 2.33 and a beta of 0.59.
Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.03). Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. The company had revenue of $4.55 billion during the quarter, compared to analysts’ expectations of $4.36 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 2.58 earnings per share for the current year.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. Barclays restated a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 5th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Friday, February 1st. They issued an “equal weight” rating on the stock. Handelsbanken lowered Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 target price on the stock. in a research note on Monday, February 4th. Finally, UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Sunday, December 2nd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $52.31.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2019/03/17/brinker-capital-inc-lowers-position-in-novo-nordisk-a-s-nvo.html.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More: The risks of owning bonds
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.